A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SP-101 Injection Following Single and Multiple Intravenous Doses in Healthy Adult Subjects
Latest Information Update: 23 Jan 2026
At a glance
- Drugs SP 101-Synphatec (Shanghai) Biopharmaceutical Technology (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; First in man
- Sponsors Synphatec (Shanghai) Biopharmaceutical Technology
Most Recent Events
- 23 Jan 2026 New trial record